Wednesday, December 24, 2025 2:42:05 PM
High-Ranking Officer e❌,
That is a “funny thing” 🤔 ..And it’s actually pretty insightful! Manufacturing is the “best possible explanation” for delay of the MAA, but it also explains the delay of industry buy-in for DC technologies overall. STANDARDIZED AUTOMATION is beginning to change that & COMBO research is fueling the motivation to speed production capabilities!
Good job, Dennis & ex!
Two Keys:
🔑 Targeted COMBOS
🔑 Scalable MANUFACTURING
Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.
Dr. Kalinski
NWBO’s IP portfolio includes more than one pipeline product in active clinical development. For example, the aDC1 platform that NWBO licensed from Roswell Park in New York has reached PII in combo with Merck’s pembrolizumab. NEXT GEN COMBOS will make some significant waves going forward!
Next Generation Dendritic Cell Treatments
Pitt BioForge
NWBO Acquires Advent BioServices
Roswell Park Dendritic Cell Technology & IP
Fud Flood 🌊
That is a “funny thing” 🤔 ..And it’s actually pretty insightful! Manufacturing is the “best possible explanation” for delay of the MAA, but it also explains the delay of industry buy-in for DC technologies overall. STANDARDIZED AUTOMATION is beginning to change that & COMBO research is fueling the motivation to speed production capabilities!
Good job, Dennis & ex!
Two Keys:
🔑 Targeted COMBOS
🔑 Scalable MANUFACTURING
Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.
Dr. Kalinski
NWBO’s IP portfolio includes more than one pipeline product in active clinical development. For example, the aDC1 platform that NWBO licensed from Roswell Park in New York has reached PII in combo with Merck’s pembrolizumab. NEXT GEN COMBOS will make some significant waves going forward!
Next Generation Dendritic Cell Treatments
Pitt BioForge
NWBO Acquires Advent BioServices
Roswell Park Dendritic Cell Technology & IP
Fud Flood 🌊
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
